Nuclear factor (NF)-κB plays a major role in the pathogenesis of B-cell neoplasms. A broad array of mostly extracellular stimuli has been reported to activate NF-κB, to various degrees, in chronic lymphocytic leukemia (CLL) cells. Because CLL cells harbor high levels of unphosphorylated (U) signal transducer and activator of transcription (STAT)-3 protein and U-STAT3 was reported to activate NF-κB, we sought to determine whether U-STAT3 activates NF-κB in CLL. Using the electrophoretic mobility shift assay (EMSA) we studied peripheral blood low-density cells from 15 patients with CLL and found that CLL cell nuclear extracts from all the samples bound to an NF-κB DNA probe, suggesting that NF-κB is constitutively activated in CLL. Immunoprecipitation studies showed that STAT3 bound NF-κB p65, and confocal microscopy studies detected U-STAT3/NF-κB complexes in the nuclei of CLL cells, thereby confirming these findings.
Introduction

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western
Hemisphere. CLL is characterized by a dynamic imbalance between the proliferation and apoptosis of neoplastic B-lymphocytes co-expressing CD5 and CD19 antigens, leading to the accumulation of these cells in the peripheral blood, bone marrow, and lymphatic tissues (1) . Several mechanisms have been reported to provide CLL cells with a survival advantage. One such mechanism involves the activation of nuclear factor (NF)-κB (2-8).
NF-κB plays an important role in the survival and proliferation of normal and neoplastic B cells. In CLL, NF-κB has been found to be activated, to a variable degree, regardless of disease stage or treatment status (2) (3) (4) (5) (6) (7) (8) , suggesting that NF-κB might be a target for therapy in CLL (9) (10) (11) .
The NF-κB family of transcription factors consists of p50, p52, p65 (RelA), c-Rel, and complex (IKKα). This allows for nuclear translocation of p52, along with RelB, and induction of NF-κB-regulated genes (12) .
NF-κB is activated in CLL by several different mechanisms: interaction with stroma cells (13) , activation of the tumor necrosis factor receptor (TNFR) family members (14) (15) (16) (17) , activation of the cell surface receptor CD40 by its ligand CD154 (4, 18, 19) , activation of the B-cell receptor (20) , activation of Notch signaling (21) , induction of nitric oxide synthase (22) , deregulation of the caspase-recruitment domain (CARD) membraneassociated guanylate kinase protein 1 (23) , deregulation of the T cell leukemia/lymphoma-1 (TCL1) oncogene (24) , induction of glycogen synthase kinase-3β (GSK-3β) (25) , and modulation of epigenetic regulators (26) .
In 2005, Yang et al. described another, previously unknown, mechanism of NF-κB activation (27) . They found that unphosphorylated (U) signal transducer and activator of transcription (STAT)-3 binds to the NF-κB dimers p65/p50 in competition with IκB. The U-STAT3/NF-κB complex translocates to the nucleus, binds to DNA, and activates NF-κB-regulated genes. We recently found that STAT3, constitutively phosphorylated on serine 727 residues in CLL cells, induces the production of STAT3 protein and that CLL cells harbor high levels of U-STAT3 (28) . Therefore, we sought to determine whether, as in other cellular systems (29) , U-STAT3 activates NF-κB in CLL cells. 
Electrophoretic mobility shift assay (EMSA)
Non-denatured nuclear extracts were prepared using the NE-PER extraction kit (Thermo Scientific, Rockford, IL). Two micrograms of nuclear protein were incubated with a biotin-labeled NF-κB p65 binding-site DNA probe (5'-AGTTGAGGGGACTTTCCCAGGC-3'; synthesized by Sigma Genosys, The Woodlands, TX) in binding buffer for 30 minutes on ice. Following incubation, the samples were separated on a 5% polyacrylamide gel in Tris-borate EDTA, transferred onto a nylon membrane, and fixed on the membrane by ultraviolet cross-linking. The biotin-labeled probe was detected with strepavidinhorseradish peroxidase (Gel-Shift Kit; Panomics, Fremont, CA). As a negative control, we used a probe lacking nuclear extracts. The competition control consisted of up to 7-fold excess unlabeled cold probe combined with the biotin-labeled probes. Cell pellets were lysed in ice-cold radioimmunoprecipitation (Ripa) assay buffer containing 1mM sodium orthovanadate, 10 mM sodium fluoride, 100 μM ethylenediaminetetraacetic acid (EDTA), 5 mM β-glycerol phosphate, 1 μg/mL aprotinin, 0.4 mM benzamidine, 1 μg/mL antipain, 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 μg/mL leupeptin, and 1 μg/mL trypsin inhibitor soybean. The lysed cell pellets were incubated on ice for 5 minutes and vortexed for 1 minute. Then, cell debris was eliminated by centrifugation at 14,000 rpm for 15 minutes, supernatants were harvested, and the protein concentration was determined using the Micro BCA protein assay reagent kit (Thermo Scientific, Pierce, Rockford, IL). Whole-cell lysates were incubated with 4 µg of polyclonal rabbit anti-human STAT3 antibodies (Upstate Cell Signaling Solutions/Millipore, Billerica MA) for 16 hours at 4°C. Protein A agarose beads (Upstate Cell Signaling Solutions) were added for 2 hours at 4°C. As a negative control, whole-cell lysates were incubated with either rabbit serum and protein A agarose beads or protein A agarose beads only. After 3 washes with Ripa assay buffer, the beads were resuspended in sodium dodecyl sulfate (SDS) sample buffer, boiled for 5 minutes, and removed by centrifugation. The supernatant proteins were separated by SDSpolyacrylamide gel electrophoresis (PAGE) (as described below in "Western blot analysis") and subsequently probed with mouse anti-human NF-κB P65 antibodies (Cell Signaling Technology, Beverly, MA).
Western blot analysis
Western immunoblotting was performed as previously described (28) . Briefly, cell pellets were lysed in ice-cold Ripa assay buffer, incubated on ice for 5 minutes, and vortexed for 1 minute. Then, cell debris was eliminated by centrifugation at 14,000 rpm for 15 minutes, supernatants were harvested, and the protein concentration was determined using the Micro BCA protein assay reagent kit (Thermo Scientific). Supernatant proteins were denatured by boiling for 5 minutes in SDS, separated by SDS-PAGE using either 5% or 10% density gels, and transferred to a nitrocellulose membrane. After transfer, equal loading was verified by Ponceau staining. 
Confocal microscopy
CLL low-density cells were cytospun on poly-L-lysine-coated slides and fixed in 3.7% formaldehyde for 15 minutes at room temperature on a shaker. The slides were then washed 3 times with PBS, incubated with 1% Triton X-100 for 5 minutes at room temperature, and washed 3 more times with PBS before blocking with mouse serum for 1 hour. After blocking, the slides were washed in PBS and incubated overnight with PElabeled mouse anti-human -STAT3 antibody (BD Biosciences) and AlexaFluor 488-labeled mouse anti-human NF-κB (BioLegend, San Diego, CA). After incubation, the slides were washed three times in PBS and then mounted with Vectashield hard set (Vector Laboratories, Burlingame, CA). The mounted slides were viewed using an Olympus FluoView 500 laser scanning confocal microscope (Olympus America, Houston, TX), and the images were analyzed using FluoView software (Olympus). 
RNA purification and quantitative real-time PCR
RNA was isolated using an RNeasy purification procedure (Qiagen, Inc.). RNA quality and concentration were analyzed with a NanoDrop spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, Delaware). Ten micrograms of total RNA was used for one- 
Results
NF-κB is constitutively activated in CLL cells
Several investigators have reported that NF-κB is activated, to various degrees, in CLL cells (2) (3) (4) (5) (6) (7) (8) . To confirm these observations, we obtained PB CLL cells and, by using EMSA, assessed NF-κB-DNA binding. We studied randomly chosen PB samples from 15 patients with CLL who had favorable or unfavorable prognostic factors and different stages of disease ( Table 1 ). As shown in Fig. 1 , we found that nuclear extracts from the PB cells of all 15 patients formed complexes with the NF-κB DNA probe, and the addition of excess (5-fold) unlabeled (cold) probe inhibited the binding. These data suggest that NF-κB was constitutively activated in the CLL cells of all studied patients.
STAT3 binds NF-κB in CLL cells, and the U-STAT3/NF-κB complex translocates to the nucleus
The p65/p50 heterodimer is the prototype NF-κB transcription factor that is crucial for the expression of genes encoding several cytokines and pro-inflammatory mediators. To determine whether STAT3 binds NF-κB in CLL cells, as previously reported in another cellular system (29), we immunoprecipitated STAT3 protein with rabbit anti-human STAT3 antibodies, and detected NF-κB p65 and p50, and STAT3 proteins in the immunoprecipitate by western blotting using mouse anti-human p65, p50, and STAT3 antibodies, respectively. As shown in Fig. 2A , the NF-κB p65 and p50 proteins were detected in CLL cell STAT3 immunopreciptate obtained from 3 different PB CLL samples.
To further delineate this observation, p65 protein was immunoprecipitated with mouse anti-human p65 antibodies, and STAT3, serine pSTAT3, p65, and p50 proteins were detected by western blot analysis. As shown in Fig. 2B, p65, p50 To confirm this observation, we conducted confocal microscopy studies. In normal PB CD19+ cells, faint signals of STAT3 were detected, as we previously reported (28) .
Scattered signals of the NF-κB p65 protein were detected in the cytoplasm and the nucleus in these control cells (Fig. 3A) , likely as a result of the constant shuttling of IκBα/NF-κB complexes between the nucleus and the cytoplasm (30) . In contrast, in CLL cells (characterized by an overwhelmingly big nucleus and a thin cytoplasm (28)), dense signals of STAT3 and of the p65 form of NF-κB, as well as STAT3/p65 complexes, were detected mainly in the nucleus and, to a lesser extent, in the cytoplasm (Fig. 3B) .
U-STAT3/NF-κB complexes bind to DNA and activate NF-κB-regulated genes
To determine whether U-STAT3/NF-κB complexes bind to DNA we isolated nuclear extracts from CLL cells and, using EMSA, assessed binding of CLL cell nuclear proteins to the κB binding site. As shown in Fig. 4A , we found that both anti-p65 and anti-STAT3 antibodies, added to the DNA biotinylated probe, induced a supershift, suggesting that the bands detected by EMSA consisted not only of NF-κB subunits but of STAT3 protein as well. To further delineate this finding, we infected CLL cells with retroviral STAT3-shRNA and, using EMSA examined the binding of CLL cell nuclear extracts to the biotinylated NF-κB p65 binding-site DNA probe. As shown in Fig. 4B , infection of CLL cells with retroviral STAT3-shRNA (previously found to downregulate STAT3 mRNA and protein levels (28)), but not with empty virus, significantly attenuated the binding of NF-κB heterodimers to DNA. To determine whether U-STAT3/NF-κB complexes bind to the promoters of NF-κB genes we used ChIP. As shown in Fig. 5A , anti-STAT3 antibodies coimmunoprecipitated DNA of STAT3, and the NF-κB-regulated genes VEGF C, CCL5 and CXCR5. Then, we asked whether U-STAT3/NF-κB complexes activate NF-κB-regulated genes. As shown in Fig. 5B , STAT3-shRNA downregulated mRNA levels of the NF-κB-regulated genes VEGF C, CCL5, and CXCR5 (which are not regulated by STAT3 (31, 32) ) and, as previously reported (28), STAT3-shRNA downregulated STAT3 mRNA. Taken together, these data suggest that U-STAT3/NF-κB complexes bind to DNA and activate NF-κB-target genes. 
Discussion
In the current study we show that NF-κB was constitutively activated in CLL cells from 15 patients with CLL, regardless of disease stage or treatment status. Several groups have demonstrated that NF-κB is activated in CLL (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) and that its activation is mediated by different, mostly extracellular, stimuli (4, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Usually, the activation of NF-κB is transient and cyclical in the presence of a continuous stimulus. For example, in mouse fibroblasts maintained by tumor necrosis factor (TNF), NF-κB-DNA binding appears and disappears every 30 to 60 minutes owing to repeated degradation and re-synthesis of IκB and the consequent activation and inactivation of NF-κB, respectively (33) . Because NF-κB is constitutively activated in CLL, we assumed that the activation of NF-κB is most likely induced by an uninterrupted intracellular mechanism.
We recently found that CLL cells harbor high levels of U-STAT3, the production of which is induced by phosphoserine STAT3, constitutively upregulated in unstimulated CLL cells (28) . STAT3 dynamically shuttles in and out of the nucleus independent of its phosphorylation status (34, 35) . The shuttling of STAT3 from the cytoplasm to the nucleus requires binding of the coiled-coil domain of STAT3 to an importin-α-importin-β dimer to mediate passage through the nuclear pore complex. U-STAT3 also is constitutively exported out of the nucleus through a yet unknown mechanism. Similar to its phosphorylated forms, U-STAT3 can also affect NF-κB-regulated gene expression indirectly by binding to NF-κB and mediating its nuclear import (29, 36) . Our data are in agreement with those observations. We found that U-STAT3 binds NF-κB and that the U-STAT3/NF-κB complex shuttles to the nucleus, binds to DNA, and activates NF-κB-regulated genes. Our data suggest that STAT3 plays a key role in the constitutive activation of NF-κB in CLL cells.
A broad array of stimuli activates NF-κB, including both endogenous and exogenous ligands and physical and chemical stresses (37 proteins (e.g., TNFR-associated factors (TRAFs) and receptor-interacting proteins) to the receptor's cytoplasmic domain, and these molecules, clustered at the receptor, activate the IKK complex. IKK then phosphorylates IκB at two serine residues, which leads to its ubiquitination and degradation by the proteasome; NF-κB, free of its inhibitor, then enters the nucleus to turn on target genes (12) . This established model appears to be more complex than initially thought. The crystal structure of IκBα bound to the p65/p50 heterodimer reveals that the IκBα protein masks only the nuclear localization sequence (NLS) of p65, whereas the NLS of p50 remains exposed. The exposed NLS of p50 coupled with nuclear export sequences (NES) in IκBα and p65 leads to constant shuttling of IκBα/NF-κB (p50/p65) complexes between the nucleus and the cytoplasm, despite steady state localization that appears almost exclusively cytosolic (30) . Our confocal microscopy data showing NF-κB in the nucleus of normal B lymphocytes agree with this observation. Degradation of IκBα drastically alters the dynamic balance between cytosolic and nuclear localization signals to favor nuclear localization of NF-κB.
Apparently, NF-κB might be activated without the degradation of IκB (29, 36) , as we now show in CLL cells.
Several investigators have suggested that NF-κB should be considered a target for therapy in CLL (9-11). We have recently reported that STAT3-shRNA reduced STAT3 mRNA and protein levels and induced apoptosis in CLL cells (28) . In the current study, we demonstrate that STAT3-shRNA inhibits the activity of NF-κB. Whether the STAT3 inhibitors currently being studied in clinical trials in CLL would also inhibit NF-κB activity remains to be determined. Abbreviations: Yr., years; WBC, white blood cells; lymph., lymphocytes; Hb., hemoglobin; Plts., platelets; β 2 M, β 2 microglobulin; M, male; F, female; N/A, not available; V H mutation, hypermutation of the immunoglobulin heavy chain gene presented as N (negative; if % derivation from the germline sequence is < 2%) or Y (positive, if % derivation from germline sequence is > 2%); Ritux., Rituxan; GM, granulocyte-macrophage colony-stimulating factor; FCR, cyclophosphamide, fludarabine, and rituxan; CFAR, cyclophosphamide, fludarabine, alemtuzumab, and rituxan; Pos., positive (analyzed by immunohistochemistry only); Neg., negative; t, translocation; del, deletion. 
